Moleculin Biotech (MBRX) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free MBRX Stock Alerts $4.32 -0.14 (-3.14%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesMay 16, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 15, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 14, 2024 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 13, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 9, 2024 | prnewswire.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 8, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 7, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataMay 2, 2024 | prnewswire.comMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024May 1, 2024 | prnewswire.comMoleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinApril 26, 2024 | finanznachrichten.deJTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamApril 18, 2024 | markets.businessinsider.comMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 18, 2024 | prnewswire.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 12, 2024 | investing.comMoleculin Biotech Inc (MBRX)April 10, 2024 | markets.businessinsider.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 10, 2024 | prnewswire.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 26, 2024 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 25, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 10:03 AM with a stated reason of "LULD pause." Trading set to resume at 10:03 AM. March 25, 2024 | markets.businessinsider.comMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLMarch 25, 2024 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 23, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023March 22, 2024 | finance.yahoo.comMoleculin Biotech Inc Reports Fiscal Year 2023 Financial ResultsMarch 22, 2024 | prnewswire.comMoleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 07:03 PM with a stated reason of "News pending."March 21, 2024 | investing.comMoleculin Biotech announces 1-for-15 reverse stock splitMarch 21, 2024 | benzinga.comA Preview Of Moleculin Biotech's EarningsMarch 20, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock SplitMarch 20, 2024 | prnewswire.comMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastMarch 19, 2024 | finance.yahoo.comMoleculin Announces Reverse Stock SplitMarch 12, 2024 | finance.yahoo.comMoleculin to Present at the 36th Annual ROTH ConferenceFebruary 6, 2024 | finance.yahoo.comHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3December 21, 2023 | finance.yahoo.comMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketDecember 15, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Moleculin Biotech (MBRX) with Buy RecommendationDecember 14, 2023 | markets.businessinsider.comBuy Rating for Moleculin Biotech Amid Promising Annamycin Trial Results in AMLDecember 11, 2023 | markets.businessinsider.comMoleculin Presents Preliminary Efficacy Data Of Annamycin In Acute Myeloid LeukemiaDecember 11, 2023 | finance.yahoo.comMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual MeetingDecember 1, 2023 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)November 14, 2023 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comMoleculin Biotech gains after early data for lead cancer therapyNovember 13, 2023 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Third Quarter 2023 Financial Results Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. MBRX Media Mentions By Week MBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.000.76▲Average Medical News Sentiment MBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼11▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCNX News Today RVPH News Today CLNN News Today XLO News Today IMRX News Today EYEN News Today HCWB News Today ACXP News Today LPCN News Today NRXP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored